Quetiapine Extended Release (XR) for the Treatment of Menopausal Depression

• Status: Completed
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

The study was designed to examine the efficacy and tolerability of quetiapine XR for the treatment of women who suffer from depression in the context of the menopausal transition and postmenopausal years. Besides the improvement of depressive symptoms, the investigators are interested in examining the impact of this medication on vasomotor symptoms (hot flashes, night sweats), sleep and overall quality of life.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: McMaster University
• Treatments: Quetiapine Fumarate

Criteria

Inclusion Criteria:

• women 40 to 60 years

• diagnosis of MDD

• perimenopausal or postmenopausal

Exclusion Criteria:

• using HRT

• using psychotropic medications

• other DSM-IV axis I diagnoses other than MDD